Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Protagonist raises $40m to test oral peptides in IBD

This article was originally published in Scrip

Executive Summary

Protagonist Therapeutics raised $40m in Series C venture capital to take its first oral peptide drug candidate PTG-100 into clinical trials for the treatment of inflammatory bowel diseases (IBD).

You may also be interested in...



Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor

J&J's Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL-23 inhibitor for Crohn's disease, which hits a similar target as two key assets in J&J's immunology portfolio: Stelara and the Phase III biologic guselkumab.

Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities

The number of US biopharma IPOs during the first 11 months of 2016 – 29 companies went public – is less than half of the 2015 total of 62, but stock performance has improved as investors focus on quality.

Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow

Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel